Who Should You Talk to If You Want to Leave a Clinical Trial?

Your wishes and circumstances can change after joining a trial. Symptoms, work, family responsibilities or how you feel about the research may all prompt another discussion. You can tell the study team: “I would like to discuss whether to continue and what would happen if I stop.”

Voluntary participation and the ability to withdraw are central research ethics principles. The 2024 Declaration of Helsinki states that refusing or withdrawing from research should not harm the patient–physician relationship or standard care. That does not mean deciding on your own how to stop medication; a responsible clinician should explain the medical transition.

Start with the study doctor or designated contact.

Use the official details in your consent form, participant information or hospital documents. A research nurse or coordinator can arrange a conversation, but symptoms, treatment changes and ongoing care need clinical assessment. Keep your usual care team informed where relevant.

If the usual contact is unavailable, use the alternative or out-of-hours route provided by the study. Do not wait for withdrawal paperwork before seeking help for a medical issue that needs timely attention. Explain what happened, when it started, what medicines you are taking and what concerns you most.

Be specific about what you want to stop.

You might want to stop the study medicine while considering some safety checks. You might not want further hospital visits or calls. You may also have questions about later access to records or use of samples. Explain your wishes, then ask how each choice would be handled. US HHS guidance on withdrawal distinguishes stopping an intervention from ending other research activities; arrangements in other settings and individual studies require separate confirmation.

One way to begin is: “I want to stop study treatment, but I am willing to hear which checks could protect my safety. I want to discuss other follow-up separately. Please explain what happens to existing information and samples.” This is a conversation aid, not a replacement for your preferences or the study documents.

Plan the next medical steps as well as the paperwork.

When would a final assessment happen? Does medication need adjustment? Who discusses and arranges the next treatment? When is your next clinical appointment? Who transfers records and treatment information between teams? Keep a written record of the answers.

The study doctor may also recommend ending treatment because of safety, changes in disease or protocol requirements. Ask for the reason and clarify whether it means stopping one medicine, all study treatment or all participation. Those states may involve different follow-up arrangements.

Do not assume all existing information will be deleted.

In research within the scope of US HHS guidance, previously collected data may be retained for analysis after withdrawal. This is not a single rule that can be applied to every country. Ask separately about existing data, future collection and samples, and where to raise privacy or participant-rights questions. The HHS explanation of data retention provides background for its stated setting.

If you feel pressured or are unsure whom to ask, check the participant-rights or ethics committee contact details in your consent information. The NCI material on participant safety explains the role of these protections. A family member you choose can help record the discussion.

Try to leave with three clear answers: “What am I stopping? Who continues to provide my care? What safety and information arrangements should I understand?” Reconsidering participation deserves clear communication, respect and a workable transition.